compound glp-1 fda says that the shortage is over The FDA is proposing the

A simple prostate-specific antigen blood test, a blood pressure check or lab work to monitor cholesterol and glucose can give us the early warning signs we need to keep you healthy and active

It is always better to wait for a replacement than to inject a compromised substance

These medications are contraindicated in patients with personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2

So what is it

On note, GLP-1 receptor agonists arent advised for individuals who: Have had Neuroendocrine tumours (NETs) or medullary thyroid cancer or have a genetic predisposition to the disease